Table 3. Most frequent adverse events in the included studies.
| Study | Drug | Most frequent AE: n/N (%) |
|---|---|---|
| Herring et al. 14 (2016): trial 1 | SUV 20/15 mg; SUV 40/30 mg |
Somnolence: 13/254 (5.1); 40/383 (10.7) |
| SUV 20/15 mg; SUV 40/30 mg |
Nasopharyngitis: 18/254 (7.1) ; 32/383 (8.4) |
|
| Herring et al. 14 (2016): trial 2 | SUV 20/15 mg; SUV 40/30 mg |
Somnolence: 20/239 (8.4); 40/387 (10.3) |
| Michelson et al. 15 (2014) | SUV 30/40 mg | Somnolence: 69/521 (13.2) |
| Black et al. 20 (2017) | ALM 100 mg; ALM 200 mg |
Headache: 18/186 (9.7); 26/176 (14.8) |
| Fan et al. 16 (2017) | SUV 40 mg | Headache: 7/60 (11.7) |
|
Rosenberg et al.
23
(2019):
SUNRISE 1 |
LEM 5 mg; LEM 10 mg |
Headache: 17/266 (6.4) ; 13/268 (4.9) |
| LEM 5 mg; LEM 10 mg |
Somnolence: 11/266 (4.1); 19/268 (7.1) |
|
| Dauvilliers et al. 21 (2019) | DAR 5 mg; DAR 10 mg; DAR 25 mg; DAR 50 mg |
Headache: 6/60 (10); 5/58 (8.6); 5/60 (8.3); 5/61 (8.2) |
|
Kärppä et al.
18
(2020)
SUNRISE 2 |
LEM 5 mg; LEM 10 mg |
Somnolence: 27/314 (8.6); 41/314 (13.1) |
| LEM 5 mg; LEM 10 mg |
Headache: 28/314 (8.9); 21/314 (6.7) |
|
| Mignot et al. 22 (2022): trial 1 | DAR 25 mg; DAR 50 mg |
Nasopharyngitis: 21/310 (7); 20/308 (6) |
| Mignot et al. 22 (2022): trial 2 | DAR 25 mg; DAR 10 mg |
Nasopharyngitis: 13/308 (4); 32/306 (12) |
Abbreviations: AE, adverse event; ALM, almorexant; DAR, daridorexant; LEM, lemborexant; n, number of patients with an event; N, total number of patients; SUV, suvorexant.
Note: In some cases, the most reported adverse event differed depending on the dose of the same drug. Numbers in bold represent the most frequent AEs for that specific formulation.